PURPOSE: To evaluate the efficacy of the Esclera @entity5692 ( @entity5692 ) treatment and its impact on clinical testing for moderate to severe @entity2194 ( @entity2194 ). DESIGN: Prospective interventional case series. METHODS: A total of 41 eyes from 25 @entity1 with moderate to severe @entity2194 were evaluated for the Esclera @entity5692 treatment. Best-corrected visual acuity (BCVA), tear osmolarity, the Schirmer I test, @entity937 ( @entity937 ), corneal and conjunctival staining, meibomian grading, and Ocular Surface Disease Index and SF-36v2 questionnaires were assessed before and after the @entity5692 treatment. These values were compared to assess the real benefit of using @entity5692 as a treatment for @entity2194 . RESULTS: Forty-one eyes from 25 @entity1 were fitted with @entity5692 for management of @entity2194 . The underlying diseases were @entity6715 (22 eyes), @entity10632 (11 eyes), graft-vs-host disease (2 eyes), @entity936 after keratomileusis in  situ (2 eyes), and undifferentiated @entity2194 (4 eyes). BCVA improved from 0.703    0.55 logMAR with habitual correction to 0.406    0.43 logMAR with @entity5692 (P < .001). There was a significant decrease in tear osmolarity values (338.1    27.1 to 314.25    38.8 mOsm/L, P < .001) and van Bijsterveld scores (3.63    2.33 to 2.63    2.46 grade, P  = .015) between the baseline and 12  months after @entity5692 wear. There were also significant improvements in @entity936 and quality of life as assessed by the OSDI and SF-36v2 questionnaires (both with P  <  .001). CONCLUSIONS: The Esclera @entity5692 treatment had a positive impact on tear osmolarity and van Bijsterveld score, as well as an improvement in the @entity1 ' BCVA, @entity936 , and quality of life.

The Use of the Esclera Scleral Contact Lens in  the  Treatment of Moderate to Severe XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity2194 :: ('MESH:D005128', 'Disease') :: ['ocular surface disease', 'dry eye disease', 'DED'] @entity6715 :: ('MESH:D013262', 'Disease') :: ['Stevens-Johnson syndrome'] @entity937 :: ('MESH:D012167', 'Disease') :: ['TBUT', 'tear film breakup time'] @entity936 :: ('MESH:D015352', 'Disease') :: ['dry eye symptoms', 'dry eye'] @entity10632 :: ('MESH:D012859', 'Disease') :: ['Sjogren syndrome'] @entity5692 :: ('MESH:D015422', 'Disease') :: ['scleral contact lens', 'SCL']
@entity2194 :: (MESH:D005128,Disease) :: ['Dry  Eye  Disease']
